selected publications
- Age 60 or older is an independent predictor of outcomes after thiotepa-based autologous transplant in primary CNS lymphoma: a CIBMTR analysis. Bone marrow transplantation. 2025 Letter GET IT
- Outcomes of Terminal Complement Blockade in Adults with High-Risk Transplant-Associated Thrombotic Microangiopathy: A Comparative Analysis. Transplantation and cellular therapy. 2025 Academic Article GET IT
- Single-cell spatial mapping reveals dynamic bone marrow microarchitectural alterations and enhances clinical diagnostics in MDS. 2025 GET IT
- Wild-type p53 overexpression in NPM1-mutated acute myeloid leukemia: potential implications for disease biology and therapy response. Haematologica. 2025 Academic Article GET IT
-
Microbiome-based prediction of allogeneic hematopoietic stem cell transplantation outcome.
Genome medicine.
2025
Academic Article
GET IT
Times cited: 2 - Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse post-transplant. Blood advances. 2025 Academic Article GET IT
- Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation. Blood advances. 2025 Academic Article GET IT
-
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.
Nature medicine.
2025
Academic Article
GET IT
Times cited: 17 - Total body irradiation primes CD19-directed CAR T cells against large B-cell lymphoma. 2025 GET IT
-
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.
Bone marrow transplantation.
2025
Academic Article
GET IT
Times cited: 5 -
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy.
Haematologica.
2025
Academic Article
GET IT
Times cited: 4 - A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation. Leukemia & lymphoma. 2024 Academic Article GET IT
-
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma.
Blood advances.
2024
Academic Article
GET IT
Times cited: 16 -
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort.
Transplantation and cellular therapy.
2024
Academic Article
GET IT
Times cited: 4 -
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.
Blood advances.
2024
Academic Article
GET IT
Times cited: 17 -
Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile.
British journal of haematology.
2024
Academic Article
GET IT
Times cited: 11 -
Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight.
Frontiers in immunology.
2024
Academic Article
GET IT
Times cited: 12 -
Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.
Blood advances.
2024
Academic Article
GET IT
Times cited: 8 - Under AI's lens: spotting mutations visually. Blood advances. 2024 Editorial Article GET IT
-
Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study.
Bone marrow transplantation.
2024
Academic Article
GET IT
Times cited: 12 -
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation.
Hematology. American Society of Hematology. Education Program.
2023
Review
GET IT
Times cited: 4 -
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.
JAMA oncology.
2023
Academic Article
GET IT
Times cited: 5 -
Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study.
Blood advances.
2023
Academic Article
GET IT
Times cited: 4 -
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma.
Transplantation and cellular therapy.
2022
Academic Article
GET IT
Times cited: 25 -
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.
Leukemia.
2022
Academic Article
GET IT
Times cited: 68 -
Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel.
Leukemia & lymphoma.
2022
Academic Article
GET IT
Times cited: 11 -
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma.
Transplantation and cellular therapy.
2022
Academic Article
GET IT
Times cited: 10 -
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT.
Blood advances.
2022
Academic Article
GET IT
Times cited: 29 -
Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma.
Transplantation and cellular therapy.
2022
Academic Article
GET IT
Times cited: 36 -
Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis.
Blood advances.
2022
Academic Article
GET IT
Times cited: 16 -
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2021
Academic Article
GET IT
Times cited: 125 -
Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.
Journal of the American College of Cardiology.
2021
Academic Article
GET IT
Times cited: 126 -
High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma.
Bone marrow transplantation.
2021
Academic Article
GET IT
Times cited: 10 -
Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
Acta haematologica.
2021
Academic Article
GET IT
Times cited: 6 -
Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry.
The Lancet. Haematology.
2021
Academic Article
GET IT
Times cited: 28 -
Patterns of salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation.
Blood advances.
2020
Academic Article
GET IT
Times cited: 48 -
Machine learning and artificial intelligence in haematology.
British journal of haematology.
2020
Review
GET IT
Times cited: 100 -
LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation.
Bone marrow transplantation.
2020
Academic Article
GET IT
Times cited: 15 -
Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
The Lancet. Haematology.
2019
Academic Article
GET IT
Times cited: 200 -
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.
Bone marrow transplantation.
2019
Academic Article
GET IT
Times cited: 15 -
Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation.
European journal of haematology.
2019
Academic Article
GET IT
Times cited: 43 -
External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.
Blood advances.
2019
Academic Article
GET IT
Times cited: 84 -
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
Blood advances.
2019
Academic Article
GET IT
Times cited: 26 -
The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation.
Leukemia.
2018
Academic Article
GET IT
Times cited: 42 -
Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2018
Academic Article
GET IT
Times cited: 30 -
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Nature communications.
2017
Academic Article
GET IT
Times cited: 148 -
Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2017
Review
GET IT
Times cited: 35 -
An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017
Academic Article
GET IT
Times cited: 31 -
Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort.
American journal of hematology.
2017
Academic Article
GET IT
Times cited: 35 -
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.
Blood.
2016
Academic Article
GET IT
Times cited: 271 -
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Blood.
2016
Academic Article
GET IT
Times cited: 262